CanSino Biologics Inc. Announces CS-2032 Zoster Vaccine Obtains Clinical Trial Approval from Canada
CanSino Biologics Inc. announced that, the Recombinant Zoster Vaccine developed by the Group in co-operation with Vaccitech Limited has received a No Objection Letter for clinical trials from Health...